ATAI Stock Soars On Track For Best Day On Trump Psychedelics Push And Wall Street Cheers

• Canaccord analyst Sumant Kulkarni raised the firm's price target on AtaiBeckley to $15 from $14 and kept a ‘Buy’ rating on the shares.
• Atai is now preparing for its investigational psychedelic drug BPL-003 to enter a late-stage trial this quarter.
• Further, data from Atai’s mid-stage trial of VLS-01 in treatment-resistant depression is expected in the second half of 2026.

Shares of AtaiBeckley Inc. (ATAI) surged 28% on Monday and are on track for their best single-day gain if the rally holds, following analyst price target hikes and growing optimism across the psychedelic drug sector after President Trump signed an executive order to accelerate research in the field.

Trump on Saturday signed an executive order instructing the U.S. Food and Drug Administration to expedite the review of psychedelic drugs, while also committing $50 million to federal research into the psychedelic compound called ibogaine.

The move boosted shares of companies including Definium Therapeutics (DFTX), Compass Pathways (CMPS), Enveric BioSciences (ENVB), and Psyence Biomedical (PBM), among others.

Wall Street Boost

Separately, Canaccord analyst Sumant Kulkarni raised the firm's price target on AtaiBeckley to $15 from $14 and kept a ‘Buy’ rating on the shares. Atai is now preparing for BPL-003 to enter a late-stage trial this quarter. The investigational drug is a fast-acting psychedelic designed for treatment-resistant depression (TRD) and alcohol use disorder.

The analyst now expects the company to price BPL-003 at a net annual price of $30,000 at launch, in line with Janssen Pharmaceuticals's Spravato nasal spray already approved for treatment-resistant depression. Further, data from Atai’s mid-stage trial of VLS-01 in TRD is expected in the second half of 2026, the analyst noted.

Guggenheim, meanwhile, raised the firm's price target on AtaiBeckley to $16 from $11 and kept a ‘Buy’ rating on the shares on Friday. The firm said that it recently met with Atai management, which reinforced its "conviction" in the BPL-003 program heading into late-stage initiation this quarter, the analyst told investors.

According to data from Koyfin, all 14 analysts covering ATAI rate it ‘Buy’ or higher. The 12-month average price target on the stock is $13.83, representing a potential upside of about 166% from current trading levels.

How Did Retail Traders React?

On Stocktwits, retail sentiment around ATAI stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘extremely high’ levels.

A Stocktwits user expressed optimism about the stocks of psychedelic drug developers including ATAI to “trend up for a while.” “This will be a good ride,” they said.

Another user cheered Atai’s great assets and voiced hopes for further rallies in future.

ATAI stock has nearly quadrupled over the past 12 months. 

Read More: AGIO Stock Slumps 25% – What’s The Novo Connection?

For updates and corrections, email newsroom[at]stocktwits[dot]com.